Wyncoll and Camporota's correspondence [1] provides a valuable tool allowing clinicians the ability to assess the number needed to treat (NNT) and cost-eff ectiveness of various ventilator-associated pneumonia (VAP) prevention strategies. Subglottic secretion drainage (SSD) technology is one VAP-reduction strategy for which NNT can easily be calculated based on its established relative risk reduction.
Smulders and colleagues [2] conducted a randomized clinical trial in 150 patients receiving mechanical ventilation and found that intermittent SSD reduced the risk of VAP by 75% (P = 0.014). Utilizing Wyncoll and Camporota's table, and assuming a VAP incidence of 4%, utilizing SSD in 33 patients will prevent one episode of VAP. In the United States, the average hospital has approximately 131 patients per year who require mechanical ventilation >96 hours (unpublished observations). Utilizing SSD in these average hospitals would likely prevent four cases of VAP per year. In addition, SSD is a cost-eff ective intervention. At the assumed VAP rate of 4%, Wyncoll and Camporota determined an upper threshold of £300 ($470 USD) additional cost per 10 days of ventilation to be a cost-eff ective investment in technologies that reduce VAP by up to 75%. Costs of SSD technology interventions are beneath this threshold.
Wyncoll and Camporota's framework illustrates that use of SSD is both a clinically and cost-eff ective strategy to reduce VAP. Th e NNT demonstrates that average hospitals will observe and benefi t from these strategies. SSD technologies warrant further adoption and appropriate utilization.
Abbreviations NNT, number needed to treat; SSD, subglottic secretion drainage; VAP, ventilator-associated pneumonia.
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